Santen Pharmaceutical Co (4536) Ratios

0 Followers

Santen Pharmaceutical Co Ratios

JP:4536's free cash flow for Q2 2026 was ¥0.55. For the 2026 fiscal year, JP:4536's free cash flow was decreased by ¥ and operating cash flow was ¥0.15. See a summary of the company’s cash flow.

Ratios	TTM	Mar 26	Mar 26	Mar 25	Mar 24
Liquidity Ratios
Current Ratio	―	2.58	2.60	2.54	2.38
Quick Ratio	―	1.99	1.87	2.08	1.94
Cash Ratio	―	1.07	0.92	1.02	0.65
Solvency Ratio	―	0.44	0.44	0.34	0.02
Operating Cash Flow Ratio	―	0.70	0.50	0.78	0.42
Short-Term Operating Cash Flow Coverage	―	0.00	0.00	26.44	12.16
Net Current Asset Value	¥ ―	¥ 100.20B	¥ 101.74B	¥ 105.81B	¥ 85.44B
Leverage Ratios
Debt-to-Assets Ratio	―	0.08	0.00	0.08	0.09
Debt-to-Equity Ratio	―	0.12	0.00	0.11	0.12
Debt-to-Capital Ratio	―	0.11	0.00	0.10	0.11
Long-Term Debt-to-Capital Ratio	―	0.08	0.00	0.08	0.09
Financial Leverage Ratio	―	1.43	1.42	1.42	1.43
Debt Service Coverage Ratio	―	57.76	26.93	9.85	1.12
Interest Coverage Ratio	―	51.92	22.68	19.48	21.36
Debt to Market Cap	―	0.05	0.00	0.06	0.07
Interest Debt Per Share	―	100.51	6.09	103.09	97.33
Net Debt to EBITDA	―	-0.80	-1.27	-1.05	-1.52
Profitability Margins
Gross Profit Margin	―	54.40%	55.20%	59.18%	59.52%
EBIT Margin	―	18.74%	15.50%	12.68%	-1.06%
EBITDA Margin	―	24.73%	21.80%	18.70%	5.12%
Operating Profit Margin	―	18.74%	15.50%	17.19%	11.47%
Pretax Profit Margin	―	15.83%	16.27%	9.89%	-2.08%
Net Profit Margin	―	12.09%	12.81%	8.82%	-5.36%
Continuous Operations Profit Margin	―	11.95%	12.88%	8.84%	-5.37%
Net Income Per EBT	―	76.36%	78.77%	89.18%	257.77%
EBT Per EBIT	―	84.44%	104.93%	57.56%	-18.11%
Return on Assets (ROA)	―	8.86%	8.83%	6.11%	-3.55%
Return on Equity (ROE)	―	12.67%	12.58%	8.70%	-5.08%
Return on Capital Employed (ROCE)	―	17.44%	13.49%	15.14%	9.65%
Return on Invested Capital (ROIC)	―	13.05%	10.68%	13.42%	9.56%
Return on Tangible Assets	―	10.86%	10.64%	7.57%	-4.60%
Earnings Yield	―	7.33%	6.39%	5.11%	-3.41%
Efficiency Ratios
Receivables Turnover	―	4.16	4.06	3.34	2.60
Payables Turnover	―	3.51	3.70	5.13	4.47
Inventory Turnover	―	2.65	2.02	2.85	2.87
Fixed Asset Turnover	―	4.11	3.73	4.22	4.22
Asset Turnover	―	0.73	0.69	0.69	0.66
Working Capital Turnover Ratio	―	2.14	2.10	2.26	2.17
Cash Conversion Cycle	―	121.32	171.57	166.13	185.65
Days of Sales Outstanding	―	87.70	89.90	109.44	140.18
Days of Inventory Outstanding	―	137.65	180.42	127.88	127.17
Days of Payables Outstanding	―	104.03	98.76	71.20	81.70
Operating Cycle	―	225.35	270.33	237.32	267.35
Cash Flow Ratios
Operating Cash Flow Per Share	―	174.78	132.77	198.01	95.88
Free Cash Flow Per Share	―	155.67	111.88	168.88	32.42
CapEx Per Share	―	19.11	20.89	29.13	63.47
Free Cash Flow to Operating Cash Flow	―	0.89	0.84	0.85	0.34
Dividend Paid and CapEx Coverage Ratio	―	3.25	2.23	3.22	1.00
Capital Expenditure Coverage Ratio	―	9.15	6.36	6.80	1.51
Operating Cash Flow Coverage Ratio	―	1.79	0.00	2.07	1.03
Operating Cash Flow to Sales Ratio	―	0.20	0.15	0.24	0.13
Free Cash Flow Yield	―	10.98%	6.27%	11.89%	2.87%
Valuation Ratios
Price-to-Earnings (P/E) Ratio	―	13.63	15.65	19.55	-29.29
Price-to-Sales (P/S) Ratio	―	1.65	2.01	1.73	1.57
Price-to-Book (P/B) Ratio	―	1.73	1.97	1.70	1.49
Price-to-Free Cash Flow (P/FCF) Ratio	―	9.11	15.96	8.41	34.86
Price-to-Operating Cash Flow Ratio	―	8.11	13.45	7.17	11.79
Price-to-Earnings Growth (PEG) Ratio	―	0.32	1.62	-0.07	0.19
Price-to-Fair Value	―	1.73	1.97	1.70	1.49
Enterprise Value Multiple	―	5.87	7.93	8.18	29.10
Enterprise Value	―	435.28B	504.10B	461.56B	416.09B
EV to EBITDA	―	5.87	7.93	8.18	29.10
EV to Sales	―	1.45	1.73	1.53	1.49
EV to Free Cash Flow	―	8.02	13.75	7.45	33.13
EV to Operating Cash Flow	―	7.14	11.59	6.35	11.20
Tangible Book Value Per Share	―	601.58	684.81	603.86	508.46
Shareholders’ Equity Per Share	―	821.11	906.49	834.19	758.81
Tax and Other Ratios
Effective Tax Rate	―	0.24	0.21	0.11	-1.58
Revenue Per Share	―	860.58	890.12	823.04	720.24
Net Income Per Share	―	104.00	114.06	72.62	-38.58
Tax Burden	―	0.76	0.79	0.89	2.58
Interest Burden	―	0.84	1.05	0.78	1.97
Research & Development to Revenue	―	0.08	0.09	0.08	0.10
SG&A to Revenue	―	0.28	0.31	0.30	0.34
Stock-Based Compensation to Revenue	―	0.00	0.00	0.00	0.00
Income Quality	―	1.68	1.16	2.73	-2.48

Currency in JPY